TP53 and cancer: Consistent with regulation of RRM1 and RRM2 by mTORC1, rapamycin treatment led to downregulation of both RRM1 and RRM2 in these TP53 wild type and mutant cancer cells, accompanied with reduction of pS6-S235/6.